Stryker (NYSE:SYK) Shares Sold Off Rep. Thomas H. Kean, Jr.

Posted by Paula Ricardo on Jul 18th, 2026

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Stryker Corporation (NYSE:SYK). In a filing disclosed on July 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Stryker stock on June 2nd. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 6/30/2026.
Sold $1,001 – $15,000 in shares of S&P Global (NYSE:SPGI) on 6/29/2026.
Sold $1,001 – $15,000 in shares of Markel Group (NYSE:MKL) on 6/29/2026.
Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 6/29/2026.
Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 6/24/2026.
Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 6/24/2026.
Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 6/22/2026.
Sold $1,001 – $15,000 in shares of Gildan Activewear (NYSE:GIL) on 6/17/2026.
Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 6/4/2026.
Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 6/2/2026.

Stryker Stock Down 3.4%

NYSE SYK traded down $11.42 on Friday, hitting $319.78. 2,459,748 shares of the stock were exchanged, compared to its average volume of 2,485,470. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The company has a market cap of $122.59 billion, a PE ratio of 37.01, a PEG ratio of 2.05 and a beta of 0.77. The company has a 50-day moving average price of $312.69 and a 200-day moving average price of $336.82.

Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts anticipate that Stryker Corporation will post 14.99 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is currently 40.74%.

Insider Activity at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 323,264 shares of company stock worth $100,659,489 in the last quarter. Company insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Evercore set a $350.00 price target on Stryker in a report on Monday, July 6th. Leerink Partners dropped their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. JPMorgan Chase & Co. cut their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Wells Fargo & Company decreased their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Finally, Argus set a $370.00 price target on Stryker in a report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $392.52.

Read Our Latest Research Report on SYK

Institutional Trading of Stryker

Hedge funds and other institutional investors have recently made changes to their positions in the company. VanderPol Investments L.L.C. boosted its holdings in shares of Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after acquiring an additional 28 shares during the period. KCM Investment Advisors LLC raised its holdings in shares of Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after buying an additional 28 shares during the last quarter. Rossby Financial LCC boosted its stake in shares of Stryker by 6.6% during the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after buying an additional 28 shares during the period. Tcfg Wealth Management LLC boosted its stake in shares of Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after buying an additional 29 shares during the period. Finally, Mechanics Financial Corp grew its holdings in shares of Stryker by 1.2% during the fourth quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock worth $864,000 after buying an additional 30 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

Positive Sentiment: Stryker launched Mako RPS, a new handheld robotic power system for total knee replacement, expanding its Mako robotics portfolio beyond robotic-arm assisted surgery and potentially broadening adoption of robotic-assisted orthopedic procedures. Stryker expands Mako robotics portfolio with full market release of Mako RPS
Positive Sentiment: Media coverage highlighted the full U.S. commercial launch of Mako RPS, reinforcing investor optimism that Stryker is strengthening its competitive position in orthopedic robotics. Stryker fully launches Mako robotic power system for knee surgery in US
Positive Sentiment: Unusually heavy call-option buying suggested traders were positioning for more upside in SYK, which can sometimes add momentum to the shares.
Positive Sentiment: RBC Capital reiterated its Buy rating on Stryker, providing another favorable signal from the analyst community. RBC Capital Sticks to Their Buy Rating for Stryker (SYK)
Neutral Sentiment: MarketWatch noted that Stryker stock outperformed peers on a strong trading day, indicating relative strength but without a specific new company catalyst. Stryker Corp. stock outperforms competitors on strong trading day
Neutral Sentiment: Analyst commentary on Stryker was mixed in broader healthcare-sector coverage, but no major negative surprise was indicated in the headlines provided. Analysts Offer Insights on Healthcare Companies: Shionogi & Co (OtherSGIOF) and Stryker (SYK)

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Stryker Company Profile

(Get Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.